90800-42-3

Basic information

• Product Name: 6-Quinolinecarboxylic acid,8-hydroxy-
• Synonyms: 8-Hydroxy-chinolin-6-carbonsaeure
• CAS NO: 90800-42-3
• Molecular Formula: C₁₀H₇NO₃
• Molecular Weight: 189.17
• Mol File: 90800-42-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 6-Quinolinecarboxylic acid,8-hydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Quinolinecarboxylic acid,8-hydroxy-(90800-42-3)
• EPA Substance Registry System: 6-Quinolinecarboxylic acid,8-hydroxy-(90800-42-3)

Safety Data

• Hazardous Substances Data: 90800-42-3(Hazardous Substances Data)

Usage

General Description

6-Quinolinecarboxylic acid,8-hydroxy- is a chemical compound that is also known by the name quinolin-8-ol carboxylic acid. It is a derivative of quinoline and contains a hydroxyl group at the 8th position of the quinoline ring. 6-Quinolinecarboxylic acid,8-hydroxy- has potential applications in the pharmaceutical and agrochemical industries due to its unique molecular structure and reactivity. It can be used as a building block in the synthesis of various drugs and pesticides. Additionally, it has been studied for its potential biological activities and therapeutic effects, making it a subject of interest for further research and development.

Upstream product

• 321-70-0 6-trifluoromethyl-quinolin-8-ol 
• 2374-03-0 4-aminosalicylic acid 
• 107-02-8 acrolein 
• 402-17-5 2-nitro-5-trifluoromethylphenol 
• 454-82-0 2-hydroxy-4-(trifluoromethyl)aniline 
• 402-14-2 2-nitro-5-(trifluoromethyl)aniline 
• 63435-16-5 3-hydroxy-4-aminobenzoic acid methyl ester 
• 56-81-5 glycerol 

Downstream Products

• 89-00-9 Pyridine-2,3-dicarboxylic acid 

Relevant articles and documents

ANTIVIRAL HETEROCYCLIC COMPOUNDS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Development of new cathepsin b inhibitors: Combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives

Human cathepsin B has many house-keeping functions, such as protein turnover in lysosomes. However, dysregulation of its activity is associated with numerous diseases, including cancers. We present here the structure-based design and synthesis of new cathepsin B inhibitors using the cocrystal structure of 5-nitro-8-hydroxyquinoline in the cathepsin B active site. A focused library of over 50 compounds was prepared by modifying positions 5, 7, and 8 of the parent compound nitroxoline. The kinetic parameters and modes of inhibition were characterized, and the selectivities of the most promising inhibitors were determined. The best performing inhibitor 17 was effective in cell-based in vitro models of tumor invasion, where it significantly abrogated invasion of MCF-10A neoT cells. These data show that we have successfully explored the structure-activity relationships of nitroxoline derivatives to provide new inhibitors that could eventually lead to compounds with clinical usefulness against the deleterious effects of cathepsin B in cancer progression.